Clinical Trials
142 trialsNCT03934840 2026-05-26
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03860987 2026-05-22
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05848011 2026-05-22
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
Phase 2 Completed
NCT04947254 2026-05-15
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03431350 2026-05-11
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04262154 2026-05-11
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05689021 2026-05-11
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Phase 2 Active not recruiting
NCT07005154 2026-05-01
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT03436654 2026-04-27
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT03821792 2026-04-15
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT02703623 2026-03-06
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04748042 2026-03-06
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
NCT01786265 2026-02-20
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03263650 2026-02-17
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03565835 2026-01-26
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Montefiore Medical Center
Phase 2 Completed
NCT04267887 2026-01-20
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT02949284 2026-01-07
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT06384222 2025-12-30
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
University of California, San Francisco
Phase 2 Recruiting
NCT07299292 2025-12-23
Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)
SMED Clinical Research
Phase 2 Recruiting
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT04175431 2025-12-18
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
University of Washington
Phase 2 Recruiting
NCT03833921 2025-12-11
APRE
Baylor College of Medicine
Phase 2 Recruiting
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT03012321 2025-10-21
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Northwestern University
Phase 2 Active not recruiting
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06971211 2025-05-14
PARTOM
First Hospital of China Medical University
Phase 2 Recruiting
NCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT01309672 2025-02-26
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
SWOG Cancer Research Network
Phase 2 Completed
NCT01254864 2025-01-27
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04869488 2025-01-24
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT02807805 2024-12-18
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
University of California, Davis
Phase 2 Active not recruiting
NCT04812366 2024-12-16
GUNS
University of British Columbia
Phase 2 Recruiting
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04992026 2024-12-05
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT03414034 2024-11-07
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Cardiff Oncology
Phase 2 Completed
NCT06505278 2024-08-05
The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06500247 2024-07-15
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
Qilu Hospital of Shandong University
Phase 2 Not yet recruiting